» Articles » PMID: 3340289

Azathioprine Toxicity During Long-term Immunosuppression of Generalized Myasthenia Gravis

Overview
Journal Neurology
Specialty Neurology
Date 1988 Feb 1
PMID 3340289
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

In this uncontrolled study, 104 patients with generalized myasthenia gravis treated with azathioprine for a median period of 29 months (range, 1 month to 12 years) were surveyed for possible adverse reactions. These occurred in 36 patients (35%) in the following order of frequency: hematologic (18%), gastrointestinal (13%), infectious diseases (13%), and elevation of liver enzymes (6%). No allergic skin reactions were observed. Azathioprine had to be discontinued temporarily in a total of 11 patients (11%) because of possible side effects. The cause of death in the nine patients who died during the period of observation (up to 12 years) was related to myasthenic crisis in two patients. In five patients, a malignant tumor was diagnosed (two carcinoma of the prostate, one ovarian carcinoma, one bronchial carcinoma, and one renal lymphoma) after 2.5 years, 6 months, 3 months, 5 years, and 6 years of treatment, respectively. A causal relationship seems unlikely in the first four cases, but cannot be excluded in the one case of late lymphoma.

Citing Articles

Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study.

Chanson J, Bouhour F, Aube-Nathier A, Mallaret M, Vial C, Hacquard A J Neurol. 2023; 270(12):5819-5826.

PMID: 37592137 DOI: 10.1007/s00415-023-11925-6.


Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

Menon D, Bril V Drugs. 2022; 82(8):865-887.

PMID: 35639288 PMC: 9152838. DOI: 10.1007/s40265-022-01726-y.


Current Treatment of Myasthenia Gravis.

Alhaidar M, Abumurad S, Soliven B, Rezania K J Clin Med. 2022; 11(6).

PMID: 35329925 PMC: 8950430. DOI: 10.3390/jcm11061597.


Treatment of Myasthenia Gravis.

Farmakidis C, Pasnoor M, Dimachkie M, Barohn R Neurol Clin. 2018; 36(2):311-337.

PMID: 29655452 PMC: 6690491. DOI: 10.1016/j.ncl.2018.01.011.


Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A J Neurol. 2016; 263(8):1473-94.

PMID: 26886206 PMC: 4971048. DOI: 10.1007/s00415-016-8045-z.